Annual Congress: Hematologic Malignancies
Save the dates! The NCCN 2024 Annual Congress: Hematologic Malignancies™ will take place Friday, September 20, 2024 – Saturday, September 21, 2024, at the New York Marriott Marquis in New York, New York.
Continuing Education
The NCCN 2023 Annual Congress: Hematologic Malignancies™ recorded sessions are available in the NCCN Continuing Education Portal.
Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, this program featured presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematologic malignancies. This program was approved for AMA PRA Category 1 Credit™ and ABIM, ABPath, and ABMS MOC for physicians and was also certified for credit for nurses, pharmacists, and other oncology professionals.
Disease areas covered:
- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Chronic Myeloid Leukemia (CML)
- Classical Hodgkin Lymphoma (CHL)
- Mantle Cell Lymphoma (MCL)
- Multiple Myeloma (MM)
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Neoplasms (MPN)
- Waldenström Macroglobulinemia (WM)
Additional topics:
- Anticoagulation and Antithrombotic Therapy
- Bispecific T-cell Engagers
- BTK Inhibitors
- Graft-Versus-Host Disease
- Toxicities in CAR T-cell Therapy
- Updates in WHO/ICC Classification System
For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.
This activity is supported through educational grants from:
- AstraZeneca
- Bristol Myers Squibb
- Genentech, a member of the Roche Group
- GSK
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lilly
- Novartis
- Sanofi
- Seagen
- Taiho Oncology, Inc.
This educational activity is supported by a medical education grant from:
- Karyopharm Therapeutics
This educational activity is supported by independent educational grants from:
- AbbVie
- Daiichi Sankyo
- Incyte Corporation
- Merck & Co., Inc., Rahway, NJ, USA.
This activity is supported by an unrestricted educational grant provided by:
- Prothena Biosciences Ltd, Dublin, Ireland, a member of the Prothena Corporation plc group
Supported by a grant from:
- Pfizer Inc.
Supported by an educational grant from:
- Servier Pharmaceuticals LLC.
Exhibition Hall
For exhibitor opportunities, contact Jennifer Tredwell, Vice President, Marketing and Communications
2023 Commerical Sponsors
Gold
BeiGene
Incyte Corporation
Janssen Oncology
Silver
Eli Lilly and Company
Pharmacyclics LLC., an AbbVie Company
Bronze
Jazz Pharmaceuticals
Karyopharm Therapeutics, Inc.
Patient Advocacy Pavilion Sponsors
Ruby
Emerald
AstraZeneca
BeiGene
Coherus
Eisai
Incyte
Invitae
Janssen Oncology
Topaz
AbbVie
AmerisourceBergen
GSK
Heron Therapeutics, Inc.
Jade
Important Alert About Fraudulent Sites
Information about this Congress may appear on fraudulent websites that appear to offer registration, exhibit space, and hotel rooms at discounted rates. These companies are in no way affiliated with NCCN or the Hilton San Francisco Union Square. Please do not book any registrations or reservations through these sites, and register only through NCCN. If you have any questions or concerns, contact conferences@nccn.org.